Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1

Journal of Medical Virology

Volumn 78, Issue 2, 2006, Pages 141-147

  Perez Alvarez L ^a   Carmona, R ^a   Ocampo, A ^b   Asorey, A ^c   Miralles, C ^b   Perez De Castro S ^c   Pinilla, M ^a   Contreras, G ^a   Taboada, J A ^d   Najera R ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Complejo Hospitalario Xeral Cíes ^*  (Spain)

^c Hospital Mexoeiro   (Spain)

^d Consellería de Sanidade da Xunta de Galicia ^*  (Spain)

Author keywords

Dynamic of resistance mutations to T20; Fusion inhibitor; gp41; HR1; HR2; Salvage therapy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CELL DNA; ENFUVIRTIDE; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

AMINO ACID SUBSTITUTION; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LONG TERM CARE; NONHUMAN; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; RNA ISOLATION; VIRUS GENE; VIRUS LOAD;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PROVIRUSES; RNA, VIRAL; SALVAGE THERAPY; SEQUENCE ALIGNMENT; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 31144436790     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20520     Document Type: Article

References (18)

1. Carmona R, Pérez-Alvarez L, Muñoz M, Casado G, Delgado E, Sierra M, Thomson M, Vega Y, Vázquez de Parga E, Contreras G, Medrano L, Nájera R. 2005. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 32:248-253.
2. Cervia JS, Smith MA. 2003. Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 37:1102-1106.
3. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E. 2001. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 75:8605-8614.
4. Greenberg ML, Cammack N. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54:333-340.
5. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L, the NIH/NIAID/DAIDS/ACTG virology laboratories. 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS clinical trials group. J Clin Microbiol 30:1787-1794.
6. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer P, D'Aquila RT. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 37:1095-1101.
7. Katlama C, Raffi F, Saag M, Wilkinson M, Chung J, Smiley L, Salgo M. 2004. Week 12 response as a predictor of week 48 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the TORO studies. In 44th ICAAC. Washington, DC, USA. Abstract H-583.
8. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 78:4628-4637.
9. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. 2004. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 48:3253-3259.
10. Miller MD, Hazuda DJ. 2004. HIV resistance to the fusion inhibitor enfuvirtide: Mechanisms and clinical implications. Drug resist updates 7:89-95.
11. Poveda E, Rodes B, Labernardiere JL, Benito JM, Toro C, Gonzalez-Lahoz J, Faudon J-L, Clavel F, Schapiro J, Soriano V. 2004. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 74:21-28.
12. Rimsky LT, Shugars DC, Matthews TJ. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72:986-993.
13. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:1787-1794.
14. Villahermosa ML, Thomson M, Vázquez de Parga E, Cuevas MT, Contreras G, Pérez-Álvarez L, Delgado E, Manjón N, Medrano L, Nájera R. 2000. Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load. J Hum Virol 3:27-34
15. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905.
16. Wild C, Greenwell T, Matthews T. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 9:1051-1053.
17. Xu L, Pozniak A, Wilfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D. 2004. Evolution of HR1 and HR2 mutations in HIV-1 gp41 associated with long-term enfuvirtide therapy. In Proceedings of the Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, abstract 659.
18. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D. 2005. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 49:1113-1119.